Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 11/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 8/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16236759 | 0.93 | ADK (0.47) | ADKSLC29A1HTR6 | |
| SCHEMBL18044685 | 0.92 | ADK (0.51) | ADKSLC29A1MTORRAB9A | |
| SCHEMBL6866845 | 0.88 | ADK (0.47) | ADKSLC29A1MTORRAB9A | |
| SCHEMBL20351805 | 0.88 | ADK (0.47) | ADKSLC29A1HTR6 | |
| SCHEMBL16236916 | 0.85 | MTOR (0.50) | ADKMTORRAB9A | |
| SCHEMBL16236390 | 0.83 | ADK (0.54) | ADKSLC29A1MTORRAB9A | |
| SCHEMBL29484542 | 0.83 | ADK (0.54) | ADKSLC29A1MTORRAB9A | |
| SCHEMBL6866005 | 0.82 | ADK (0.47) | ADKSLC29A1 | |
| SCHEMBL2969987 | 0.82 | ADK (0.47) | ADKSLC29A1 | |
| SCHEMBL2969985 | 0.82 | ADK (0.47) | ADKSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682083-B2 | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-20 | — | — | US | disclosed |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-06-16 | — | — | US | disclosed |
| EP-2997030-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-03-23 | — | — | EP | disclosed |
| WO-2014184069-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | RET, DCK, PRKD2 | ADK 64/4885SLC29A1 1578/4885HTR6 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.